Pictet Asset Management SA Boosts Holdings in uniQure (NASDAQ:QURE)

Pictet Asset Management SA grew its position in shares of uniQure (NASDAQ:QUREGet Rating) by 39.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 164,535 shares of the biotechnology company’s stock after purchasing an additional 46,332 shares during the period. Pictet Asset Management SA’s holdings in uniQure were worth $3,067,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in QURE. Nisa Investment Advisors LLC raised its stake in shares of uniQure by 60.0% during the first quarter. Nisa Investment Advisors LLC now owns 4,000 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 1,500 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of uniQure by 16.4% in the first quarter. Envestnet Asset Management Inc. now owns 60,334 shares of the biotechnology company’s stock worth $1,090,000 after buying an additional 8,479 shares during the last quarter. Banque Pictet & Cie SA increased its stake in shares of uniQure by 4.0% in the first quarter. Banque Pictet & Cie SA now owns 79,041 shares of the biotechnology company’s stock worth $1,428,000 after buying an additional 3,059 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of uniQure in the first quarter worth $224,000. Finally, IndexIQ Advisors LLC increased its stake in shares of uniQure by 1,824.0% in the first quarter. IndexIQ Advisors LLC now owns 23,146 shares of the biotechnology company’s stock worth $418,000 after buying an additional 21,943 shares during the last quarter. Hedge funds and other institutional investors own 86.46% of the company’s stock.

uniQure Stock Performance

QURE stock opened at $22.18 on Monday. The company has a market capitalization of $1.04 billion, a P/E ratio of -8.25 and a beta of 0.96. The company has a 50-day simple moving average of $19.43 and a 200 day simple moving average of $18.92. uniQure has a fifty-two week low of $12.52 and a fifty-two week high of $30.41. The company has a quick ratio of 7.20, a current ratio of 7.26 and a debt-to-equity ratio of 0.24.

Insider Buying and Selling

In related news, VP Alexander Edward Kuta III sold 2,306 shares of the company’s stock in a transaction dated Wednesday, September 21st. The shares were sold at an average price of $18.65, for a total value of $43,006.90. Following the completion of the sale, the vice president now owns 92,890 shares of the company’s stock, valued at $1,732,398.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on QURE. Chardan Capital dropped their price target on shares of uniQure from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. StockNews.com initiated coverage on shares of uniQure in a report on Wednesday, October 12th. They issued a “sell” rating for the company. TheStreet downgraded shares of uniQure from a “c-” rating to a “d” rating in a report on Tuesday, August 9th. Wells Fargo & Company decreased their price objective on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, August 9th. Finally, William Blair reaffirmed an “outperform” rating on shares of uniQure in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.43.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Featured Articles

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure (NASDAQ:QUREGet Rating).

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.